Literature DB >> 16936371

Neoadjuvant chemotherapy before surgery of hepatoblastoma.

K V Udupa1, S M Navadgi, P Mullerpatan, D Chhabra, R C Shah, P Jagannath.   

Abstract

Though surgical resection is the main stay of treatment for childhood hepatoblastoma (HB), many are unsuitable for radical surgery at diagnosis due to extensive intrahepatic and/or extra hepatic disease. We report experience in five patients of HB from a single institution (2001-2005) with preoperative Neoadjuvant chemotherapy (NACT) followed by surgery. Three patients received cisplatin, doxorubicin; and two cisplatin / vincristine /5-fluorouracil. All showed more than 50% reduction in tumor size confirmed by CT scan. Hepatic resection R0 was performed in all. There was no chemotherapy related toxicity nor post surgical morbidity or mortality. All are disease free at median follow up of 4 years. NACT produces adequate down staging of the HB with acceptable toxicity. Though cisplatin with doxorubicin produced good results, new protocol with cisplatin, vincristine and 5FU is promising without cardiotoxicity.

Entities:  

Mesh:

Year:  2006        PMID: 16936371     DOI: 10.1007/BF02898456

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   5.319


  6 in total

1.  Advanced hepatoblastoma: successful liver resection following preoperative chemotherapy.

Authors:  S Roy Choudhury; Dharmendra Singh
Journal:  Trop Gastroenterol       Date:  2004 Jan-Mar

Review 2.  SIOPEL trials using preoperative chemotherapy in hepatoblastoma.

Authors:  G Perilongo; E Shafford; J Plaschkes
Journal:  Lancet Oncol       Date:  2000-10       Impact factor: 41.316

3.  Midterm results with hepatectomy after preoperative chemotherapy in hepatoblastoma.

Authors:  Minu Bajpai; K Pal; S Agarwala; Tulika Seth; Arun K Gupta
Journal:  Pediatr Surg Int       Date:  2005-04-19       Impact factor: 1.827

4.  Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach--results of the first prospective study of the International Society of Pediatric Oncology.

Authors:  J Pritchard; J Brown; E Shafford; G Perilongo; P Brock; C Dicks-Mireaux; J Keeling; A Phillips; A Vos; J Plaschkes
Journal:  J Clin Oncol       Date:  2000-11-15       Impact factor: 44.544

Review 5.  Where do we stand with hepatoblastoma? A review.

Authors:  J Marco Schnater; S Eleonore Köhler; Wouter H Lamers; Dietrich von Schweinitz; Daniël C Aronson
Journal:  Cancer       Date:  2003-08-15       Impact factor: 6.860

6.  Risk-adapted treatment for childhood hepatoblastoma. final report of the second study of the International Society of Paediatric Oncology--SIOPEL 2.

Authors:  G Perilongo; E Shafford; R Maibach; D Aronson; L Brugières; P Brock; M Childs; P Czauderna; G MacKinlay; J B Otte; J Pritchard; R Rondelli; M Scopinaro; C Staalman; J Plaschkes
Journal:  Eur J Cancer       Date:  2004-02       Impact factor: 9.162

  6 in total
  2 in total

1.  Hepatoblastoma: a single institutional experience of 18 cases.

Authors:  Parul J Shukla; Savio G Barreto; Sajid S Qureshi; Rohini Hawaldar; Shailesh V Shrikhande; Mukta R Ramadwar; Shripad Banavali
Journal:  Pediatr Surg Int       Date:  2008-05-06       Impact factor: 1.827

2.  Hepatoblastoma: Analysis of treatment outcome from a tertiary care center.

Authors:  Sanju Cyriac; Ramakrishnan Ayloor Seshadri; Arun Warrier; Tenali Gnana Sagar
Journal:  J Indian Assoc Pediatr Surg       Date:  2011-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.